CHARLES RIVER LABORATORIES INTERNATIONAL INC
For the period ended Dec 28, 2024. Filed Feb 19, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 19, 2025
CRL$353.34+4.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets and
(in thousands, except per share amounts)
| December 28, 2024 | December 30, 2023 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $194,606 | $276,771 |
| Trade receivables and contract assets, net of allowances for credit losses of $18,301 and $25,722, respectively | 720,915 | 780,375 |
| Inventories | 278,544 | 380,259 |
| Prepaid assets | 103,210 | 87,879 |
| Other current assets | 105,796 | 83,378 |
| Total current assets | 1,403,071 | 1,608,662 |
| Property, plant and equipment, net | 1,604,014 | 1,639,741 |
| Venture capital and strategic equity investments | 218,350 | 243,811 |
| Operating lease right-of-use assets, net | 412,490 | 394,029 |
| Goodwill | 2,846,608 | 3,095,045 |
| Intangible assets, net | 723,400 | 864,051 |
| Deferred tax assets | 42,179 | 40,279 |
| Other assets | 278,233 | 309,383 |
| Total assets | $7,528,345 | $8,195,001 |
| Liabilities, Redeemable Noncontrolling Interests and Equity | ||
| Current liabilities: | ||
| Accounts payable | $140,337 | $168,937 |
| Accrued compensation | 179,418 | 213,290 |
| Deferred revenue | 248,322 | 241,820 |
| Accrued liabilities | 232,010 | 227,825 |
| Other current liabilities | 194,014 | 203,210 |
| Total current liabilities | 994,101 | 1,055,082 |
| Long-term debt, net and finance leases | 2,240,205 | 2,647,147 |
| Operating lease right-of-use liabilities | 483,789 | 419,234 |
| Deferred tax liabilities | 106,960 | 191,349 |
| Other long-term liabilities | 195,212 | 223,191 |
| Total liabilities | 4,020,267 | 4,536,003 |
| Commitments and contingencies (Notes 2, 11, 13, and 18) | ||
| Redeemable noncontrolling interests | 41,126 | 56,722 |
| Equity: | ||
| Preferred stock, $0.01 par value; 20,000 shares authorized; no shares issued and outstanding | — | — |
| Common stock, $0.01 par value; 120,000 shares authorized; 51,141 shares issued and outstanding as of December 28, 2024 and 51,338 shares issued and outstanding as of December 30, 2023 | 511 | 513 |
| Additional paid-in capital | 1,966,237 | 1,905,578 |
| Retained earnings | 1,812,100 | 1,887,218 |
| Treasury stock, at cost, zero shares as of December 28, 2024 and December 30, 2023 | — | — |
| Accumulated other comprehensive loss | (317,345) | (196,427) |
| Total Charles River Laboratories International, Inc. equity | 3,461,503 | 3,596,882 |
| Nonredeemable noncontrolling interest | 5,449 | 5,394 |
| Total equity | 3,466,952 | 3,602,276 |
| Total liabilities, redeemable noncontrolling interests and equity | $7,528,345 | $8,195,001 |
| See Notes to Consolidated Financial Statements. | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.